FOLH1 and prostate cancer: Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein receptor, expressed in normal prostate tissue and to a greater extent in prostate carcinoma, making it a useful target for radionuclide imaging and therapy for prostate cancer [5–7].